You’re using a public version of DrugPatentWatch with free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Georgia, Republic of: These 8 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025

DrugPatentWatch® Estimated Loss of Exclusivity Dates in Georgia, Republic of

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Georgia, Republic of: These 8 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025" DrugPatentWatch.com thinkBiotech, 2024 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Georgia, Republic of Patent P20094655
Patent Title: PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PM 14-HYDROXYCODEINONE

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

When can VIZIMPRO (dacomitinib) generic drug versions launch?

Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Georgia, Republic of Patent P20084551
Patent Title: 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety-two patent family members in forty-eight countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Georgia, Republic of Patent P20094639
Patent Title: COATED TABLET FORMULATION AND METHOD

Drug Price Trends for KOMBIGLYZE XR
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?

Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Georgia, Republic of Patent P20094639
Patent Title: COATED TABLET FORMULATION AND METHOD

Drug Price Trends for ONGLYZA
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.

When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?

Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Georgia, Republic of Patent P20105086
Patent Title: POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR

DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has ninety-five patent family members in forty-three countries.

The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.

When can ISENTRESS (raltegravir potassium) generic drug versions launch?

Generic name: raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Georgia, Republic of Patent P20105086
Patent Title: POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR

Drug Price Trends for ISENTRESS
ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-five patent family members in forty-five countries.

See drug price trends for ISENTRESS.

The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.

When can CORLANOR (ivabradine) generic drug versions launch?

Generic name: ivabradine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Georgia, Republic of Patent P20084467
Patent Title: GAMMA CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.

When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?

Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Georgia, Republic of Patent P20084465
Patent Title: BETA-CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.